RESEARCH ARTICLE
A Large Hospital Outbreak of Klebsiella pneumoniae (DHA-1 and SHV-11 Positive): Importance of Detection and Treatment of ampC β-Lactamases
Timothy Vanwynsberghe1, Katia Verhamme2, Marijke Raymaekers3, Reinoud Cartuyvels3, Kristien Van Vaerenbergh1, An Boel1, Hans de Beenhouwer*, 1
Article Information
Identifiers and Pagination:
Year: 2009Volume: 3
First Page: 55
Last Page: 60
Publisher Id: TOIDJ-3-55
DOI: 10.2174/1874279300903010055
Article History:
Received Date: 28/04/2009Revision Received Date: 05/05/2009
Acceptance Date: 08/05/2009
Electronic publication date: 23/6/2009
Collection year: 2009
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Plasmid-borne ampC β-lactamases are emerging worldwide. There is no gold standard in detecting them so it is presumed their prevalence is underestimated. They may confer resistance to broad-spectrum cephalosporins. In this paper the first outbreak in Europe of a Klebsiella pneumoniae harbouring a plasmid-borne DHA-1 β-lactamase and a SHV-11 β- lactamase is reported. Following CLSI (Clinical Laboratories Standards Institute) guidelines the majority of isolates would have been reported susceptible to third generation cephalosporines in spite of increased MIC values. No failures were observed in patients treated with cefepime or meropenem. Infections were linked to stay on the intensive care unit and/or urological interventions. The outbreak was stopped after a meeting was organised between the department of infection control of the hospital and the complete ICU and urology staff in which the importance of strict hand hygiene to limit transmission was stressed.
